title: Does intravitreal injection of bevacizumab have an effect on the blood-aqueus barrier function?
authors.forename: F
authors.initials: F
authors.lastname: Ziemssen
authors.forename: M
authors.initials: M
authors.lastname: Warga
authors.forename: I M
authors.initials: IM
authors.lastname: Neuhann
authors.forename: M
authors.initials: M
authors.lastname: Leitritz
authors.forename: S
authors.initials: S
authors.lastname: Biester
authors.forename: S
authors.initials: S
authors.lastname: Grisanti
authors.forename: K U
authors.initials: KU
authors.lastname: Bartz-Schmidt
mesh_terms: D000368:Aged; D020533:Angiogenesis Inhibitors / Q000097:blood / Q000494:pharmacology*; D000911:Antibodies, Monoclonal / Q000097:blood / Q000494:pharmacology*; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab; D018916:Blood-Aqueous Barrier / Q000187:drug effects*; D005260:Female; D006801:Humans; D007267:Injections; D008268:Macular Degeneration / Q000188:drug therapy; D008297:Male; D014822:Vitreous Body
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000068258:Bevacizumab